Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary
Genetic Technologies (NASDAQ: GENE) has appointed Mark Ziirsen as Chief Financial Officer and Company Secretary. Ziirsen brings over 25 years of experience in senior finance leadership roles across various industries, including life sciences, technology, and consumer segments. His background includes positions with major ASX-listed companies such as Cochlear , Aristocrat Leisure , and Coca-Cola Amatil .
CEO Simon Morriss expressed confidence that Ziirsen's extensive experience will add significant value to the team. This appointment aligns with Genetic Technologies' position as a global leader in genomics-based tests for health, wellness, and serious disease. The move is expected to support the company's growth and transformation efforts in the rapidly evolving field of genomics.
- Appointment of experienced CFO with 25+ years in senior finance roles
- New CFO has experience with both ASX and Nasdaq listed companies
- Addition of expertise in scaling, growing, and transforming technology-driven businesses
- None.
MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary.
Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years’ experience operating across life sciences, technology and consumer segments that include senior finance leadership roles with major ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited. More recently, in roles as an executive, interim or non-executive director he has been supporting emerging, technology-driven businesses scale, grow, transform and raise capital.
CEO, Simon Morriss, commented, “We are pleased to have Mark join our team. His extensive experience in leadership roles across multiple industries will add enormous value to our team”.
Approved for release by the Board of Directors.
Enquiries
Simon Morriss
Chief Executive Officer
E: investors@genetype.com
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness, and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com
Forward Looking Statements
This announcement may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings with the ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
Who is the new CFO and Company Secretary of Genetic Technologies (NASDAQ: GENE)?
What experience does Mark Ziirsen bring to Genetic Technologies (NASDAQ: GENE)?
When was the appointment of the new CFO announced by Genetic Technologies (NASDAQ: GENE)?
How does Genetic Technologies (NASDAQ: GENE) describe its business focus?
